Minimal Residual Disease Detection in Mantle Cell Lymphoma: Technical Aspects and Clinical Relevance

Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Andersen, 2003, Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant, Eur J Haematol, 71, 73, 10.1034/j.1600-0609.2003.00093.x Dreyling, 2005, Blood, 105, 2677, 10.1182/blood-2004-10-3883 Vandenberghe, 2003, Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries, Br J Haematol, 120, 793, 10.1046/j.1365-2141.2003.04140.x Geisler, 2008, Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group, Blood, 112, 2687, 10.1182/blood-2008-03-147025 Bosch, 2008, Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication, Clin Cancer Res, 14, 155, 10.1158/1078-0432.CCR-07-1371 Bruggemann, 2006, Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia, Blood, 107, 1116, 10.1182/blood-2005-07-2708 Ladetto, 2002, High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO), Blood, 100, 1559, 10.1182/blood-2002-02-0621 Pott, 2006, Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma, Blood, 107, 2271, 10.1182/blood-2005-07-2845 Raff, 2007, Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials, Blood, 109, 910, 10.1182/blood-2006-07-037093 Bruggemann, 2004, Significance of minimal residual disease in lymphoid malignancies, Acta Haematol, 112, 111, 10.1159/000077566 Foroni, 1997, Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response, Leukemia, 11, 1732, 10.1038/sj.leu.2400841 Mortuza, 2002, Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia, J Clin Oncol, 20, 1094, 10.1200/JCO.20.4.1094 Moreton, 2005, Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival, J Clin Oncol, 23, 2971, 10.1200/JCO.2005.04.021 Vidriales, 2003, Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value, Blood, 101, 4695, 10.1182/blood-2002-08-2613 Neale, 2004, Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia, Leukemia, 18, 934, 10.1038/sj.leu.2403348 Dworzak, 2002, Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia, Blood, 99, 1952, 10.1182/blood.V99.6.1952 Moreton, 2005, Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival, J Clin Oncol, 23, 2971, 10.1200/JCO.2005.04.021 Bottcher, 2008, Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations, Haematologica, 93, 551, 10.3324/haematol.11267 Bottcher, 2004, Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation, Leukemia, 18, 1637, 10.1038/sj.leu.2403478 Rawstron, 2001, Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy, Blood, 98, 29, 10.1182/blood.V98.1.29 Sanchez, 2002, Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation, Leukemia, 16, 1460, 10.1038/sj.leu.2402584 Costa, 2010, Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping, Leukemia, 24, 1927, 10.1038/leu.2010.160 Brizova, 2008, Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma, Int J Cancer, 123, 2865, 10.1002/ijc.23883 Evans, 2006, Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets, Leukemia, 21, 207, 10.1038/sj.leu.2404479 van Dongen, 1991, Analysis of immunoglobulin and T cell receptor genes, Clin Chim Acta, 198, 93, 10.1016/0009-8981(91)90247-A van Dongen, 1991, Analysis of immunoglobulin and T cell receptor genes, Clin Chim Acta, 198, 1, 10.1016/0009-8981(91)90246-9 van Krieken, 2006, Improved reliability of lymphoma diagnostics via PCR-based clonality testing—report of the BIOMED-2 Concerted Action BHM4-CT98-3936, Leukemia, 21, 201, 10.1038/sj.leu.2404467 Kurokawa, 1997, Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma, Br J Haematol, 98, 408, 10.1046/j.1365-2141.1997.2133030.x van Dongen, 2003, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, 17, 2257, 10.1038/sj.leu.2403202 Aubin, 1995, Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies, Leukemia, 9, 471 Linke, 1995, Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias, Leukemia, 9, 840 Kienle, 2003, VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome, Blood, 102, 3003, 10.1182/blood-2003-05-1383 Walsh, 2003, Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma, Blood, 101, 4047, 10.1182/blood-2002-11-3479 Bruggemann, 2000, Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR, Leukemia, 14, 1419, 10.1038/sj.leu.2401831 van der Velden, 2003, Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects, Leukemia, 17, 1013, 10.1038/sj.leu.2402922 van der Velden, 2007, Analysis of minimal residual disease by Ig//TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data, Leukemia, 21, 604, 10.1038/sj.leu.2404586 Pott, 1998, Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas, Leukemia, 12, 1630, 10.1038/sj.leu.2401172 Pott, 2010, Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study, Blood, 115, 3215, 10.1182/blood-2009-06-230250 Andersen, 1997, Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease, Blood, 90, 4212, 10.1182/blood.V90.10.4212 Andersen, 2002, Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma, Exp Hematol, 30, 703, 10.1016/S0301-472X(02)00807-X van der Velden, 2006, Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease, Haematologica, 91, 679 Gribben, 1993, Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma, Blood, 81, 3449, 10.1182/blood.V81.12.3449.3449 Rosenberg, 1991, PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma, Proc Natl Acad Sci U S A, 88, 9638, 10.1073/pnas.88.21.9638 Williams, 1994, Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement, Ann Oncol, 5, 71, 10.1093/annonc/5.suppl_1.S71 Siebert, 1998, Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas, Ann Oncol, 9, 519, 10.1023/A:1008242729509 Tsujimoto, 1984, Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation, Science, 224, 1403, 10.1126/science.6610211 Williams, 1991, Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes, Blood, 78, 493, 10.1182/blood.V78.2.493.493 Williams, 1995, Mantle cell/centrocytic lymphoma: molecular and phenotypic analysis including analysis of the bcl-1 major translocation cluster by PCR, Curr Top Microbiol Immunol, 194, 341 Williams, 1992, Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma, Cancer Res, 52, 5541s Rimokh, 1994, Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas, Blood, 83, 1871, 10.1182/blood.V83.7.1871.1871 Rimokh, 1993, Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias, Blood, 81, 3063, 10.1182/blood.V81.11.3063.3063 Rimokh, 1994, Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle- cell lymphomas and t(11q13)-associated leukemias, Blood, 83, 3689, 10.1182/blood.V83.12.3689.3689 Swerdlow, 2008, Mature B-cell neoplasms: mantle cell lymphoma, 229 Swerdlow, 2002, From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades, Hum Pathol, 33, 7, 10.1053/hupa.2002.30221 Voena, 1997, A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors, Leukemia, 11, 1793, 10.1038/sj.leu.2400801 Olsson, 1999, Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD), Leukemia, 13, 1833, 10.1038/sj.leu.2401575 Herrmann, 2009, Improvement of overall survival in advanced stage mantle cell lymphoma, J Clin Oncol, 27, 511, 10.1200/JCO.2008.16.8435 Foran, 2000, European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma, J Clin Oncol, 18, 317, 10.1200/JCO.2000.18.2.317 Howard, 2002, Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival, J Clin Oncol, 20, 1288, 10.1200/JCO.20.5.1288 Lenz, 2005, J Clin Oncol, 23, 1984, 10.1200/JCO.2005.08.133 Ladetto, 2008, Blood, 111, 4004, 10.1182/blood-2007-10-116749 Hiddemann, 1998, Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group, J Clin Oncol, 16, 1922, 10.1200/JCO.1998.16.5.1922 Corradini, 2004, Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes, J Clin Oncol, 22, 1460, 10.1200/JCO.2004.10.054 Ladetto, 2002, High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO), Blood, 100, 1559, 10.1182/blood-2002-02-0621 Corradini, 1995, High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting, Blood, 85, 1596, 10.1182/blood.V85.6.1596.bloodjournal8561596 Corradini, 1999, Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells, J Clin Oncol, 17, 208, 10.1200/JCO.1999.17.1.208 Martinelli, 2000, Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma, J Clin Oncol, 18, 2273, 10.1200/JCO.2000.18.11.2273 Friedberg, 2003, Ex vivo B cell depletion using the Eligix B cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma, Bone Marrow Transplant, 32, 681, 10.1038/sj.bmt.1704212 Corradini, 1997, Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting, Blood, 89, 724, 10.1182/blood.V89.2.724 Jacquy, 1999, Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?, Bone Marrow Transplant, 23, 681, 10.1038/sj.bmt.1701637 Tarella, 1999, Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions, Leukemia, 13, 1456, 10.1038/sj.leu.2401488 Magni, 2000, Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion, Blood, 96, 864, 10.1182/blood.V96.3.864 Gianni, 2003, Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen), Blood, 102, 749, 10.1182/blood-2002-08-2476 Pott, 2010, R-CHOP/R-DHAP prior to autologous stem cell transplantation induces higher rates of molecular remission than R-CHOP in younger patients with MCL: results of the MCL younger intergroup trial of the European MCL Network [abstract 965], Blood, 116, 10.1182/blood.V116.21.965.965 Khouri, 1999, Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy, Ann Oncol, 10, 1293, 10.1023/A:1008380527502 Ladetto, 2006, Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma [abstract], Biol Blood Marrow Transplant, 12, 1270, 10.1016/j.bbmt.2006.07.007 Andersen, 2009, Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma, J Clin Oncol, 27, 4365, 10.1200/JCO.2008.21.3116 Bertoni, 1999, Clonality assessment in blood of patients with mantle cell lymphoma, Leuk Lymphoma, 32, 375, 10.3109/10428199909167400 Ferrer, 2007, Leukemic involvement is a common feature in mantle cell lymphoma, Cancer, 109, 2473, 10.1002/cncr.22715 Dreger, 2007, Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome, Haematologica, 92, 42, 10.3324/haematol.10608